Stock Market News3 months Mirum Shares Surge More Than 90% in 6 Months: Here’s Why Zacks
MIRM’s lead drug, Livmarli, is driving revenues and the momentum is likely to continue. The company’s efforts to build its pipeline beyond Livmarli also hold promise.
XMIRM’s lead drug, Livmarli, is driving revenues and the momentum is likely to continue. The company’s efforts to build its pipeline beyond Livmarli also hold promise.
X